



## PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

April 7, 2021

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Apr. 7, 2021-- [PhaseBio Pharmaceuticals, Inc.](#) (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provide a company overview at the 20<sup>th</sup> Annual Needham Virtual Healthcare Conference on April 15, 2021, at 11:00am ET.

Interested parties can access the live and archived webcast of the event on the "Events and Presentations" page of the "Investors" section of the company's website at [www.phasebio.com](http://www.phasebio.com). The webcast replay will be available for 90 days after the conclusion of the live presentation.

### About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviaptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio's proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviaptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit [www.phasebio.com](http://www.phasebio.com), and follow us on Twitter [@PhaseBio](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210407005886/en/): <https://www.businesswire.com/news/home/20210407005886/en/>

### Investor Contact:

John Sharp  
PhaseBio Pharmaceuticals, Inc.  
Chief Financial Officer  
(610) 981-6506  
[john.sharp@phasebio.com](mailto:john.sharp@phasebio.com)

### Media Contact:

Will Zasadny  
Canale Communications, Inc.  
[will.zasadny@canalecomm.com](mailto:will.zasadny@canalecomm.com)  
(619) 961-8848

Source: PhaseBio Pharmaceuticals, Inc.